BMS has welcomed the recently announced listing of immunotherapy combination OPDIVO (nivolumab) in combination with YERVOY (ipilimumab) for the treatment of advanced renal cell carcinoma. …
Latest Video
New Stories
-
Who will drive discussions about cell and gene therapies?
March 21, 2019 - - Latest News -
'Extending' the 'promise of immunotherapy'
March 21, 2019 - - Latest News -
Marcus Blackmore returns to lead company
March 21, 2019 - - Latest News -
Pfizer hits the 'Bay Run' for Clean Up Australia Day
March 21, 2019 - - Latest News -
GSK announces Australian winners of research challenge
March 21, 2019 - - Latest News -
New analysis highlights political focus on PBS
March 20, 2019 - - Latest News -
A focus on new listings in the absence of anything else
March 20, 2019 - - Comment